Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2′-O-methyl-RNA

International Journal of Pharmaceutics

Volumn 419, Issue 1-2, 2011, Pages 33-42

  Dong, Meng ^a   Philippi, Claudia ^b   Loretz, Brigitta ^b,c   Nafee, Noha ^b   Schaefer, Ulrich F ^b   Friedel, Godehard ^d   Ammon Treiber, Susanne ^a,e   Griese, Ernst Ulrich ^a   Lehr, Claus Michael ^b,c   Klotz, Ulrich ^a   Mürdter, Thomas E ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d Schillerhoehe Hospital   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Inhibition; Nanoparticles; Oligonucleotide; Primary lung cells; Telomerase; Tumor tissue slices

Indexed keywords

ANTISENSE 2' O METHYL RNA; ANTISENSE OLIGONUCLEOTIDE; CHITOSAN; NANOCARRIER; NANOPARTICLE; POLYGLACTIN; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; NANOTECHNOLOGY; PRIORITY JOURNAL; RNA BINDING; TISSUE SLICE;

CARCINOMA, NON-SMALL-CELL LUNG; CHITOSAN; HUMANS; LACTIC ACID; LUNG NEOPLASMS; NANOPARTICLES; POLYGLYCOLIC ACID; RNA, ANTISENSE; TELOMERASE; TISSUE CULTURE TECHNIQUES;

EID: 80053563026     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.07.009     Document Type: Article

References (32)

1. S. Agrawal Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides Biochim. Biophys. Acta 1489 1999 53 68
2. S. Akhtar, and R.L. Juliano Cellular uptake and intracellular fate of antisense oligonucleotides Trends Cell Biol. 2 1992 139 144
3. J. Beisner, M. Dong, S. Taetz, N. Nafee, E.U. Griese, U. Schaefer, C.M. Lehr, U. Klotz, and T.E. Murdter Nanoparticle mediated delivery of 2′-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells Lung Cancer 68 2010 346 354
4. J. Beisner, M. Dong, S. Taetz, K. Piotrowska, E. Kleideiter, G. Friedel, U. Schaefer, C.M. Lehr, U. Klotz, and T.E. Murdter Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2′-O-methyl-RNA J. Pharm. Sci. 98 2009 1765 1774
5. E.H. Blackburn Telomeres Trends Biochem. Sci. 16 1991 378 381 (Pubitemid 121004477)
6. S.E. Burdall, A.M. Hanby, M.R. Lansdown, and V. Speirs Breast cancer cell lines: friend or foe? Breast Cancer Res. 5 2003 89 95 (Pubitemid 36348102)
7. W.S. Dalton The tumor microenvironment as a determinant of drug response and resistance Drug Resist. Updat. 2 1999 285 288 (Pubitemid 30070452)
8. M. Dong, T.E. Murdter, and U. Klotz Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine Eur. J. Clin. Pharmacol. 66 2010 1 3
9. E. Fattal, and G. Barratt Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA Br. J. Pharmacol. 157 2009 179 194
10. C.B. Harley Telomerase and cancer therapeutics Nat. Rev. Cancer 8 2008 167 179 (Pubitemid 351305939)
11. B. Herbert, A.E. Pitts, S.I. Baker, S.E. Hamilton, W.E. Wright, J.W. Shay, and D.R. Corey Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death Proc. Natl. Acad. Sci. U. S. A. 96 1999 14276 14281 (Pubitemid 30000641)
12. B.S. Herbert, A.E. Hochreiter, W.E. Wright, and J.W. Shay Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol Nat. Protoc. 1 2006 1583 1590
13. K. Hiyama, E. Hiyama, S. Ishioka, M. Yamakido, K. Inai, A.F. Gazdar, M.A. Piatyszek, and J.W. Shay Telomerase activity in small-cell and non-small-cell lung cancers J. Natl. Cancer Inst. 87 1995 895 902
14. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J. Clin. 60 2010 277 300
15. H. Katas, S. Chen, A.A. Osamuyimen, E. Cevher, and H.O. Alpar Effect of preparative variables on small interfering RNA loaded poly(d,l-lactide-co- glycolide)-chitosan submicron particles prepared by emulsification diffusion method J. Microencapsul. 25 2008 541 548
16. N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L. Ho, G.M. Coviello, W.E. Wright, S.L. Weinrich, and J.W. Shay Specific association of human telomerase activity with immortal cells and cancer Science 266 1994 2011 2015
17. M.N. Kumar, S.S. Mohapatra, X. Kong, P.K. Jena, U. Bakowsky, and C.M. Lehr Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents J. Nanosci. Nanotechnol. 4 2004 990 994 (Pubitemid 40056457)
18. P.J. Morin Drug resistance and the microenvironment: nature and nurture Drug Resist. Updat. 6 2003 169 172 (Pubitemid 37129916)
19. N. Nafee, S. Taetz, M. Schneider, U.F. Schaefer, and C.M. Lehr Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides Nanomedicine 3 2007 173 183 (Pubitemid 47332344)
20. A. Nyga, U. Cheema, and M. Loizidou 3D tumour models: novel in vitro approaches to cancer studies J. Cell Commun. Signal. 2011
21. C. Philippi, B. Loretz, U.F. Schaefer, and C.M. Lehr Telomerase as an emerging target to fight cancer - opportunities and challenges for nanomedicine J. Control. Release 146 2010 228 240
22. A.E. Pitts, and D.R. Corey Inhibition of human telomerase by 2′-O-methyl-RNA Proc. Natl. Acad. Sci. U. S. A. 95 1998 11549 11554
23. J.W. Shay, and W.E. Wright Telomerase therapeutics for cancer: challenges and new directions Nat. Rev. Drug Discov. 5 2006 577 584 (Pubitemid 43971192)
24. M. Sonnenberg, H. van der Kuip, S. Haubeis, P. Fritz, W. Schroth, G. Friedel, W. Simon, T.E. Murdter, and W.E. Aulitzky Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast BMC Cancer 8 2008 364
25. S. Taga, T. Osaki, A. Ohgami, H. Imoto, and K. Yasumoto Prognostic impact of telomerase activity in non-small cell lung cancers Ann. Surg. 230 1999 715 720 (Pubitemid 30191835)
26. I.F. Tannock, C.M. Lee, J.K. Tunggal, D.S. Cowan, and M.J. Egorin Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin. Cancer Res. 8 2002 878 884 (Pubitemid 34742121)
27. O. Tredan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 2007 1441 1454
28. M. Umachandran, and C. Ioannides Stability of cytochromes P450 and phase II conjugation systems in precision-cut rat lung slices cultured up to 72 h Toxicology 224 2006 14 21
29. V. Vaira, G. Fedele, S. Pyne, E. Fasoli, G. Zadra, D. Bailey, E. Snyder, A. Faversani, G. Coggi, R. Flavin, S. Bosari, and M. Loda Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors Proc. Natl. Acad. Sci. U. S. A. 107 2010 8352 8356
30. H. van der Kuip, T.E. Murdter, M. Sonnenberg, M. McClellan, S. Gutzeit, A. Gerteis, W. Simon, P. Fritz, and W.E. Aulitzky Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment BMC Cancer 6 2006 86
31. W.E. Wright, M.A. Piatyszek, W.E. Rainey, W. Byrd, and J.W. Shay Telomerase activity in human germline and embryonic tissues and cells Dev. Genet. 18 1996 173 179 (Pubitemid 26116862)
32. S. Zimmermann, and U.M. Martens Telomeres and telomerase as targets for cancer therapy Cell. Mol. Life Sci. 64 2007 906 921 (Pubitemid 46597763)